5.77
0.13 (2.3%)
0.13 (2.3%)
Upgrade to Real-Time
Afterhours
| Volume | 3,188,417 |
|
|||||
| News | - | ||||||
| Day High | 5.78 | Low High |
|||||
| Day Low | 5.56 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| CTI BioPharma Corporation | CTIC | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.13 | 2.3% | 5.77 | 16:05:59 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 5.73 | 5.56 | 5.78 | 5.76 | 5.64 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 15,560 | 3,188,417 | $ 5.67 | $ 18,085,411 | - | 1.43 - 7.80 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:23:58 | formt | 5,000 | $ 5.77 | USD |
Period:
Draw Mode:
CTI BioPharma Corporation Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 660.00M | 114.39M | 105.23M | $ - | $ - | -1.09 | -4.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | -516.35k | 6.50% |
CTI BioPharma News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical CTIC Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.68 | 5.895 | 5.33 | 5.68 | 3,849,668 | 0.09 | 1.58% |
| 1 Month | 6.04 | 6.71 | 5.33 | 6.04 | 3,875,102 | -0.27 | -4.47% |
| 3 Months | 6.01 | 7.80 | 5.26 | 6.25 | 4,397,235 | -0.24 | -3.99% |
| 6 Months | 5.18 | 7.80 | 3.32 | 5.71 | 4,432,716 | 0.59 | 11.39% |
| 1 Year | 3.03 | 7.80 | 1.43 | 4.57 | 3,853,716 | 2.74 | 90.43% |
| 3 Years | 0.89 | 7.80 | 0.62 | 3.84 | 1,904,822 | 4.88 | 548.31% |
| 5 Years | 3.19 | 7.80 | 0.6001 | 3.70 | 1,275,787 | 2.58 | 80.88% |
CTI BioPharma Description
| CTI BioPharma Corp is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic and more effective cancer therapies. Its therapeutic area is blood-related cancers. Its products under pipeline include PIXUVRI, and Pacritinib. PIXUVRI is a novel aza-anthracenedione with unique structural and physiochemical properties. Pacritinib is an investigational oral kinase inhibitor for the treatment of adult patients with myelofibrosis. |